SALIX: ACCESS FOR PATIENTS LATER THIS YEAR
Pharming's Ruconest wins FDA nod in crowded orphan HAE market
By Jennifer Boggs and Cormac Sheridan
Friday, July 18, 2014
As expected, the FDA cleared for marketing Wednesday recombinant human C1 esterase inhibitor Ruconest (conestat alpha) for use in acute attacks of hereditary angioedema (HAE), news that should bring an immediate lift to developer Pharming Group NV in the form of a $20 million milestone payment from partner Salix Pharmaceuticals Inc. due upon the first U.S. sale but offers little clarity as to how the drug will stack up against well-entrenched competitors in the crowded HAE space.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.